Novartis Zelmac Dosing Instructions Among Remaining Issues In FDA Review
Executive Summary
FDA will have to decide between a high dose or titrated regimen for Novartis' irritable bowel syndrome therapy Zelmac following a review by the Gastrointestinal Drugs Advisory Committee.
You may also be interested in...
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Novartis Zelmac Well Tolerated In Alternating IBS, Study Suggests
Novartis' constipation-predominant irritable bowel syndrome therapy Zelmac is well tolerated in patients with alternating IBS, data presented at the United European Gastroenterology Week in Brussels Nov. 28 suggests.